Behold the Body. Electron microgram of a Biondi body shows a dense core surrounded by filaments that bind gold-labeled secondary antibody to TMEM239 (black dots). [Courtesy of Ghetti et al., 2024.] ...

Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

It doesn’t replace radiologists or the clinical read, but it augments them,” he told Alzforum before its FDA approval. He would like to see it widely adopted. Other Alzheimer’s clinicians contacted by ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

Despite higher rates of clinically diagnosed dementia among people from non-white racial and ethnic groups, historically they have been underrepresented in AD clinical trials. Efforts are underway to ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...